Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 13/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070316 | 0.79 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL8380198 | 0.79 | PDE4B (0.57) | ALDH1A1TSHRKDM4E | |
| SCHEMBL2491302 | 0.78 | RARA (0.43) | ALDH1A1CYP3A4HSD17B10KDM4EGAA | |
| SCHEMBL3344619 | 0.78 | LMNA (0.50) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL5068545 | 0.77 | HSD17B1 (0.52) | ALDH1A1TSHRKDM4EHTT | |
| SCHEMBL5067710 | 0.75 | TLK2 (0.46) | ALDH1A1CYP3A4CHEK1HTTGAA | |
| SCHEMBL27659963 | 0.75 | GAA (0.43) | ALDH1A1TSHRKDM4ECHEK1HTT | |
| SCHEMBL14484688 | 0.75 | SCN4A (0.59) | KDM4EGAA | |
| SCHEMBL3342950 | 0.75 | BRD4 (0.43) | ALDH1A1CYP3A4HSD17B10TDP1KDM4E | |
| SCHEMBL27659947 | 0.74 | ALDH1A1 (0.43) | ALDH1A1CYP3A4HSD17B10TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | ALDH1A1 431/4885CYP3A4 1176/4885TSHR 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.